Search

INTRODUCTION: La Commission Régionale de Certification de l'Eradication de la poliomyélite pour l'Afrique(CRCA) en session à Brazzaville du 8 au 10 octobre 2007 avait déclaré la Mauritanie '' libérée de la poliomyélite ''. Objectif: Décrire l'épidémiologie des PFA (Paralysies flasques aigues) et évaluer les indicateurs de performance du système de surveillance pour la période de 2008 à 2012 ayant suivi cette déclaration. METHODES: Les données du service de surveillance épidémiologique ont été nettoyées et analysées à l'aide du logiciel Epi-infoversion 3.4.3 (CDC Atlanta). RESULTATS: 319 cas de PFA ont été notifié soit une incidence moyenne de 4.61/100000 enfants de moins de 15 ans par an. La distribution des cas cumulés par mois montre une importante notification des cas PFA pendant la période de Février à Juillet et à la suite de l'épidémie de 2009 alors que l'incidence des cas confirmés a été plus importante entre Novembre et Février. L'âge moyen était de 4ans (E.T. ,4ans) et 77.4% avaient un âge = 5ans. 18 cas de PFA ont été confirmés poliovirus sauvage(PVS) dont 6 en 2009 et 12 en 2010 et tous d'importation. L'âge moyen était de 3.4 ans (E.T ,2.6 ans). 44,4% étaient des filles et 55.5% garçons. Cette proportion était proche de celle des PFA non polio (45.1% versus 54.9%). 61% avaient reçu au plus une dose de vaccin polio orale (VPO) pour les cas de PFA polio contre 7.4% pour les PFA non polio. Aucune discrimination de genre na été observé sur la population des PFA ayant reçu une dose au plus (ratio-sexe= 16/17=0.94). La fièvre était présente pour 90%des cas de PFA non polio contre 85% pour les cas PVS. Cette fièvre à progresser en 3 jours pour tous les cas de PVS et pour 82,7% des cas de PFA non polio. Le taux d'hospitalisation était de 13.6% pour les cas de PFA non polio contre 89% pour les PFA polio. Dans tous les deux groupes, les membres de prédilection étaient d'abord l'un des 2 membres inférieurs de façon alternative (46.8%), ensuite les deux membres inférieurs à la fois (22.2%). En troisième lieu, un membre supérieur et un membre inférieur de façon asymétrique (5.3%) et en quatrième lieu, tous les 4 membres (4.6%). Le diagnostic final des cas de PFA non polio n'était pas rapporté pendant toute la période de l'étude, cependant, 2 cas ont été classés compatible et un cas de paralysie associée à la vaccination contre la polio a été rapporté en 2012 chez un enfant féminin de 3 ans ayant reçu sa première dose de VPO. En ce qui concerne les performances des indicateurs de la surveillance, 4 indicateurs n'ont pas atteint les performances escomptées: Le pourcentage des échantillons arrivés au laboratoire national moins de 3 jours après les prélèvements est resté en deçà des objectifs, variant entre 40% et 70%. Il en est de même des Districts de santé ayant notifies au moins un cas (50 à 68%). Le pourcentage des prélèvements dans lesquels un entérovirus non polio a été isolé a connu une évolution en dents de scie avec des valeurs de 0.0% en 2008 et en 2010 et 1.9% en 2011. L'examen de suivi du60emejour n'a concerné que les cas dont l'échantillon était jugé inadéquat au laboratoire. CONCLUSION: Les PFA qui ont été notifiés en Mauritanie de 2008 à 2012 présentent tableau clinique qui est classique, et sont notifiés avec un pic régulier en début des périodes de soudure (Mars-Juillet) suggérant l'hypothèse d'un lien écologique avec les changements de climat et de régime alimentaire. Les performances des indicateursde la surveillance des PFA sont à améliorer, notamment: 1) La compréhension des critères de jugement de la qualité des échantillons. 2) L'examen de laboratoire et l'interprétation des résultats. 3) La détermination du diagnostic final pour chaque cas de PFA non polio. 4) L'enregistrement des informations dans la base des données.

Voluntary medical male circumcision (VMMC) decreases the risk for female-to-male HIV transmission by approximately 60%, and the President's Emergency Plan for AIDS Relief (PEPFAR) is supporting the scale-up of VMMC for adolescent and adult males in countries with high prevalence of human immunodeficiency virus (HIV) and low coverage of male circumcision. As of September 2015, PEPFAR has supported approximately 8.9 million VMMCs.

In 2008, the 46 member states of the World Health Organization (WHO) African Region (AFR) adopted a measles preelimination goal to reach by the end of 2012 with the following targets: 1) >98% reduction in estimated regional measles mortality compared with 2000, 2) annual measles incidence of fewer than five reported cases per million population nationally, 3) >90% national first dose of measles-containing vaccine (MCV1) coverage and >80% MCV1 coverage in all districts, and 4) >95% MCV coverage in all districts by supplementary immunization activities (SIAs). Surveillance performance objectives were to report two or more cases of nonmeasles febrile rash illness per 100,000 population, one or more suspected measles cases investigated with blood specimens in ≥80% of districts, and 100% completeness of surveillance reporting from all districts. This report updates previous reports and describes progress toward the measles preelimination goal during 2011-2012. In 2012, 13 (28%) member states had >90% MCV1 coverage, and three (7%) reported >90% MCV1 coverage nationally and >80% coverage in all districts. During 2011-2012, four (15%) of 27 SIAs with available information met the target of >95% coverage in all districts. In 2012, 16 of 43 (37%) member states met the incidence target of fewer than five cases per million, and 19 of 43 (44%) met both surveillance performance targets. In 2011, the WHO Regional Committee for AFR established a goal to achieve measles elimination by 2020. To achieve this goal, intensified efforts to identify and close population immunity gaps and improve surveillance quality are needed, as well as committed leadership and ownership of the measles elimination activities and mobilization of adequate resources to complement funding from global partners.

Since 1997, when the goal of interrupting measles transmission by 2010 was adopted, substantial progress has been made toward the elimination of measles in the Eastern Mediterranean Region (EMR). For the 22 EMR member countries, routine coverage with the first dose of a measles-containing vaccine (MCV) increased from 70% in 1997 to 82% in 2009. All 22 countries conducted measles catch-up vaccination campaigns during 1994-2009, and most conducted follow-up campaigns as needed. Of the 22 EMR countries, 19 have established case-based surveillance for measles with laboratory confirmation. Reported measles cases decreased by 86% during 1998-2008, and estimated measles mortality decreased by 93% during 2000-2008, accounting for 17% of global measles mortality reduction during that period. Despite these successes, several significant challenges remain, and the EMR will not be able to achieve measles elimination by the end of 2010. Achieving and maintaining high population immunity with 2 doses of MCV, improving sensitive case-based surveillance, identifying and vaccinating high-risk subpopulation groups, and appropriately responding to outbreaks are key steps needed to achieve the goal., (Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2011.)

Measles was a leading cause of infant and child morbidity and mortality in Bahrain before the introduction of measles vaccine in 1974. With the establishment of the Expanded Program on Immunization (EPI) in 1981 and the introduction of a second dose of measles vaccine in 1985, coverage for first and second doses of measles vaccine increased to 94% by 1997 and has been sustained >97% since 2001. Measles, mumps, and rubella (MMR) immunization campaigns targeting 12-year-old students were conducted annually during 1998-2006 and achieved coverage of >95%. As a result, the incidence of measles in Bahrain has declined markedly over the past 4 decades, to 2.7 cases per million persons in 2009. Recent confirmed measles cases have occurred sporadically, in undervaccinated children or in infants too young or adults too old to receive measles vaccine. Bahrain has made significant progress toward measles elimination by sustaining high immunization coverage and strengthening case-based measles surveillance activities. Further success will depend on improved identification and immunization of undervaccinated expatriate workers and their families., (Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2011.)

Despite enormous challenges, Somalia has been successfully implementing accelerated measles control activities since 2005. Through innovative strategies and with the support of local and international partners, the country has shown potentials of implementing measles mortality reduction activities in complex emergencies. Measles incidence has been reduced by >80% after the measles catch-up campaigns of 2005-2007, and national reported measles routine immunization coverage with first dose measles containing vaccine has reached 59% for the first time in 2009. However, the near collapse of the health care system and the ongoing insecurity continue to hamper the implementation of recommended measles control and elimination strategies in some parts of the country, making these achievements fragile. Somalia exemplifies the challenges in meeting measles elimination goals in the World Health Organization Eastern Mediterranean region. As the region is entering its 2010 measles elimination goals, it appears necessary to establish realistic and flexible interim goals for measles control in Somalia that will take into consideration the specificities of the country. Maintaining flexibility in conducting field operations, securing financial resources, multiplying opportunities for measles vaccination, and improving disease monitoring systems will remain vital to sustain and improve current achievements., (© The Author 2011. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved.)

Measles is still one of the most common infectious killers of children in the world, especially in developing countries. In Iran, during the prevaccine era, 150,000-500,000 cases of measles were reported annually, with a death rate of 10%-15%. After the establishment of Expanded Program on Immunization program in 1984, vaccination rates for the first and second doses of measles vaccine increased to >90% by the mid-1990s, and the number of measles cases decreased to 2652 in 1996. In response to increased numbers of cases in older age groups during 1996-2002, a nationwide measles-rubella vaccination campaign was conducted in 2003, and 33,100,000 persons (99%) aged 5-25 years were vaccinated. During 2004-2009, 221 laboratory-confirmed measles cases (<1 case per million population) were detected, primarily in rural areas and among migrant groups who traveled to or came from high-incidence countries. High routine immunization coverage, low disease incidence, and surveillance system data suggest that interruption of endemic virus transmission might have already been achieved in Iran, but challenges remain and continued efforts are needed to sustain this accomplishment., (Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2011.)